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This report compares gene transfer efficiencies as well as durations and levels of gene expression for human
immunodeficiency virus (HIV) and equine infectious anemia virus (EIAV) lentiviral vectors in a variety of
human cell types in vitro. EIAV and HIV vectors transduced equivalent numbers of proliferating and G1/S- and
G2/M-arrested cells, and both had very low efficiencies of transduction into G0-arrested cells. Analysis of the
levels of both the enhanced green fluorescent protein (EGFP) and mRNA demonstrated that the HIV-
transduced cells expressed greater levels of EGFP protein and RNA than the EIAV-transduced cells. Mea-
surements of vector-derived EGFP RNA half-lives were fourfold higher with the HIV vector than with the EIAV
vector. Long-term culture of EIAV-transduced human cells showed a significant decrease in the number of cells
expressing the transgene; however, no corresponding loss was found in EIAV-transduced equine cells. In
contrast, only a moderate decrease in the number of transgene-expressing cells was seen with the HIV vectors.
Taken together, these results demonstrate that the EIAV vectors transduced human cells with efficiencies
similar to those of the HIV vectors. However, our data indicate that transgene expression from EIAV vectors
is limited by the instability of vector-derived RNA transcripts and silencing of the EIAV vectors over time.
Lentiviruses are efficient gene transfer vehicles due to their
ability to transduce both dividing and nondividing cells. The
most thoroughly investigated of the lentiviral gene therapy
vectors are derived from human immunodeficiency virus
(HIV) type 1. While significant effort has gone into HIV vector
development to maximize the biosafety of HIV vectors and
minimize the possibility of generating replication-competent
lentiviruses, significant questions remain about the biosafety of
HIV-based vectors for use in human clinical trials.
Due to these biosafety concerns, a series of gene therapy
vectors based on other primate and nonprimate lentiviruses
have been developed (1, 2, 5, 6, 10). Gene transfer vectors
based on a lentivirus, equine infectious anemia virus (EIAV),
were developed and shown to be effective in transducing pro-
liferating and G1-arrested cells in vitro and mouse neurons in
vivo (11, 14). However, the ability of EIAV vectors to trans-
duce and express in human-derived cells has not been exten-
sively investigated. The goal of this study was to directly com-
pare gene transfer efficiencies as well as levels of transgene
expression and persistence in a variety of human cell types by
using vectors derived from recombinant EIAV and HIV.
EIAV transduces human cells in vitro with an efficiency
similar to that of HIV vectors. To directly compare the trans-
duction efficiencies of HIV- and EIAV-based vectors, we trans-
duced the cell lines SupT1 (T cell; American Type Culture
Collection [ATCC] strain no. CRL1942), HepG2 (hepatocel-
lular carcinoma; ATCC no. HB8065), NB8 (neuroblastoma; a
generous gift of Vincent Kidd, St. Jude Children’s Research
Hospital, Memphis, Tenn.), 293 (fibroblast; ATCC no.
CRL1573), and NBL-6 (horse fibroblast; ATCC no. CCL57).
EIAV, HIV, and murine leukemia virus (MLV) vectors with
the internal cytomegalovirus (CMV) promoter driving the en-
hanced green fluorescent protein (EGFP) were produced by
triple transient transfection of 293 T cells, pseudotyped with
the vesicular stomatitis virus envelope glycoprotein, and con-
centrated by ultracentrifugation as described previously (14,
15). HIV and MLV vectors, non-self-inactivating vectors, were
chosen to more accurately compare gene expression levels with
that of the non-self-inactivating EIAV vector. Proliferating
and G1/S (treated with the DNA polymerase inhibitor aphidi-
colin at 10 g/ml)- and G2/M (treated with the microtubulin
inhibitor nocodazole at 5 g/ml)-arrested cells were trans-
duced at a multiplicity of infection (MOI) of 1 and analyzed for
EGFP expression at 48 h posttransduction. As shown in Table
1, there was little difference in the levels of transduction of
proliferating human cells with EIAV, HIV, and MLV vectors
(40 to 97%). Experimental data demonstrated that the num-
bers of EGFP-positive cells did not significantly differ when
analyzed at 14 days posttransduction, suggesting that the vec-
tor systems were integrated (data not shown). The levels of
gene transfer for both the EIAV and HIV vectors were also
comparable in cells arrested in G1/S (63 to 87%) and G2/M (23
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to 80%) (Table 1). As expected, the MLV-based vectors were
ineffective at transducing nondividing cells. To compare the
gene transfer levels in G0-arrested cells, the growth of cells of
the rat fibroblast cell line 208F was arrested by density-depen-
dent growth arrest for either 7 or 14 days and then the cells
were transduced at an MOI of 5 and assayed for EGFP 48 h
posttransduction. Both lentiviral vector systems were signifi-
cantly compromised in their ability to transduce G0-arrested
cells (the transduction efficiency of EIAV was 18%, and that of
HIV was 14%) compared to the ability of proliferating cells
(Table 2). Also, with both vectors, a 40% decrease in the level
of cells transduced was observed in cells arrested for 14 days
compared to that of cells arrested for 7 days, suggesting a
negative correlation between the duration of quiescence and
gene transfer efficiency. The reason for the decreased EIAV
transduction of G0 fibroblasts may be defective reverse tran-
scription or inefficient nuclear translocation of the preintegra-
tion complex, both of which have been observed with HIV
vectors (7,13). G0-arrested cells were resistant to transduction
by the MLV vectors.
We investigated whether EIAV vectors, like HIV vectors
(13), could be maintained as a stable transduction intermediate
in quiescent cells. Quiescent cells were transduced with the
various vectors at an MOI of 5. Seven days later, the quiescent
transduced cells were stimulated to proliferate by the addition
of serum-containing medium and subjected to flow cytometric
analysis 2 days later. Gene transfer levels increased four- to
sixfold with the EIAV and HIV vectors compared to those of
nonstimulated quiescent cells, whereas MLV vectors were in-
efficient at transducing the stimulated cells (Table 1). These
data suggest that, like HIV, EIAV vectors form stable trans-
duction intermediates in quiescent cells, which may be a char-
acteristic of all lentiviral vector systems.
EGFP protein levels are lower in EIAV vectors than in HIV
vectors. To directly compare transgene expression levels from
EIAV and HIV vectors, cells were transduced at an MOI of 0.5
to prevent multiple vector integration events per cell, ex-
panded, and sorted with a fluorescence-activated cell sorter for
EGFP expression 14 days later to ensure vector integration.
The EIAV long terminal repeat (E-LTR) vector was created
by excising the internal CMV promoter from the parental
EIAV vector (E-CMV), which allows transcription of the
EGFP gene to be driven solely by the E-LTR. Gene expression
was measured by flow cytometric analysis of the EGFP protein
and by Northern blot analysis. Dot blot analysis of genomic
DNA isolated from the cells sorted with a fluorescence-acti-
vated cell sorter showed that similar vector genome copy num-
TABLE 2. Average levels of transduction (n  3) of G0-arrested
rat 208 fibroblast cells with EIAV, HIV, and MLV vectors
Cells
Transduction rate of quiescent 208F rat
fibroblast EGFP-positive cells relative to
that of proliferating cells (avg  SD)
after transduction with:
EIAV vector HIV vector MLV vector
Proliferating 1 1 1
7-day-arrested G0 0.18  0.05 0.14  0.08 0.002  0.001
14-day-arrested G0 0.11  0.05 0.09  0.06 0.001
Stimulated 7-day-arrested G0
a 0.66  0.06 0.87  0.04 0.03  0.02
a Initiation of cell proliferation 4 days posttransduction of 7-day-arrested G0
cells.
TABLE 1. Average levels of transduction (n  3) of proliferating or G1 or G2 growth-arrested human cell lines
with EIAV, HIV, and MLV vectors
Cell line Cell type Cell statusa
% of cells that were EGFP positive (avg  SD)
after transduction with:
EIAV vector HIV vector MLV vector
D17 Canine osteosarcoma Proliferating 81.6  0.02 85.5  2.0 84.2  2.2
G1/S arrested 80.5  10.6 70.5  3.5 0.83  0.3
G2/M arrested 32.5  5.8 25.5  6.3 15.0  0.1
NB8 Neuroblastoma Proliferating 79.5  1.4 84.2  3.8 71.6  7.8
G1/S arrested 63.8  5.2 72.5  5.6 2.3  1.5
G2/M arrested 80.6  2.7 80.1  15.1 9.2  6.8
HepG2 Hepatic carcinoma Proliferating 39.7  0.4 59.0  12.1 57.7  3.8
G1/S arrested 64.6  1.8 71.7  2.6 2.0  1.4
G2/M arrested 40.2  1.9 82.4  0.8 7.8  2.5
293 Embryonic fibroblast Proliferating 58.0  4.5 84.5  3.4 34.3  6.0
G1/S arrested 80.2  5.2 85.9  1.8 0.4  0.3
G2/M arrested 44.3  1.3 69.2  0.6 5.2  5.4
Sup T1 T cell Proliferating 94.2  0.2 97.5  0.8 81.5  1.2
G1/S arrested 78.6  0.6 87.9  0.6 4.9  1.5
G2/M arrested ND
b ND ND
NBL-6 Horse fibroblast Proliferating 50.9  4.0 70.2  0.2 59.0  21.1
G1/S arrested 80.8  3.9 85.7  4.4 1.3  1.5
G2/M arrested 58.1  13.5 92.7  5.5 9.1  4.2
a G1/S-phase cells arrested with aphidocolin, and G2/M-phase cells arrested with nocodazole.
b ND, not done due to loss of cell viability.
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bers existed in the EIAV and HIV vector-transduced cell pop-
ulations (Fig. 1A). In all cell lines, the EGFP protein levels
were two- to fivefold lower in the E-CMV-transduced cells
than those in the HIV-transduced cells (Fig. 1B). The EGFP
protein levels obtained with the E-LTR vectors were 4- to
14-fold lower than those obtained with the E-CMV vectors,
demonstrating the necessity of internal promoters in EIAV-
based vectors.
Northern blot analysis was used to quantitate the steady-
state RNA levels in the sorted EGFP-positive cells (Fig. 1C).
We detected three RNA bands that represented the full-length
and spliced transcripts originating from the viral LTRs and an
RNA transcript originating from the internal CMV promoter.
Similar to what occurred with the protein levels, there was a
three- to fivefold decrease in the total amount of vector-de-
rived RNA (represented by the addition of transcripts from the
LTR [spliced and unspliced] and the internal CMV promoter)
from E-CMV-transduced cells compared to the amount from
the HIV-transduced cells. The steady-state levels of EGFP
RNA obtained with the E-LTR vectors were two- to ninefold
lower than those obtained with the E-CMV vectors. The level
of EGFP RNA generated by the MLV vectors was comparable
to that generated by the HIV vectors.
To assess the influence of vector sequences on promoter
activity, we analyzed the amount of EGFP RNA originating
from the internal CMV promoter only. Surprisingly, the
amount of EGFP RNA originating from the CMV promoter in
E-CMV-transduced cells was two- to eightfold less than that
originating from the HIV-transduced cells, suggesting that the
endogenous sequence element(s) found in the EIAV vector
backbone may contribute to the decreased amount of steady-
state RNAs in transduced cells. Taken together, these data
demonstrate that the differences in EGFP protein levels de-
tected by flow cytometry obtained with E-CMV and HIV vec-
tors were not due to differing translational efficiencies between
the vector systems but were the direct result of decreased
amounts of steady-state RNA produced from the EIAV-based
vectors.
Decreased stability of RNA transcripts from EIAV vectors.
Since the levels of steady-state EGFP RNAs originating from
identical internal CMV promoters from EIAV vectors were
less than those originating from HIV vectors in all cell lines
examined, we hypothesized that these differences may be due
to differences in mRNA stability between the vector systems.
Actinomycin D (10 g/ml)-treated transduced NB8 cells were
analyzed for their EGFP RNA half-life by Northern blot anal-
ysis (Fig. 2). The half-life of transcripts originating from the
internal CMV promoter in the E-CMV vector was 6 h. In
FIG. 1. Analysis of gene expression from vector-transduced cells. Cells were transduced with the various vectors at an MOI of 0.5, expanded
for 14 days, and sorted for EGFP expression. (A) Dot blot analysis of vector copies. DNA (30 g) from the sorted EGFP cells (10 g of DNA
from NBL-6 cells) was spotted onto a nylon filter and probed with 32P-labeled EGFP cDNA. Lane M, mock-transduced. (B) Flow cytometric
analysis of EGFP protein levels in sorted EGFP-positive cells transduced with the different vectors. Results are the mean levels of channel
fluorescence (MCF) of EGFP-expressing cells and were normalized to the minimum gate setting. (C) Northern blot analysis of sorted EGFP-
positive cells. Total RNAs were isolated from the sorted cells, and the blot was sequentially probed with 32P-labeled EGFP and -actin. -Actin
was used to normalize for RNA loading. Arrows indicate the unspliced and spliced messages originating from viral LTRs and the transcripts
originating from the internal CMV promoter. Mock, mock transduced. Data shown are representative of the gene expression levels observed from
multiple experiments.
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contrast, the half-life of transcripts originating from the inter-
nal CMV promoter in HIV vectors was 24 h, a finding consis-
tent with the data from the study of Zufferey et al. (17). The
half-lives of RNAs derived from both the EIAV and HIV
vectors in HepG2 cells, 293 cells, and the horse fibroblast cell
line NBL-6 were similar to those found in the NB8 cells (data
not shown), demonstrating that the short RNA half-lives of
EIAV vector transcripts do not vary markedly between cell
types or in a species-specific manner. Surprisingly, transcripts
from the E-LTR vector lacking the internal CMV promoter
were dramatically more labile than transcripts from other len-
tiviral vectors, with half-lives of less than 4 h. These data
suggest that the low levels of steady-state RNAs from EIAV
vectors are due, in part, to the inherent instability of EIAV-
derived transcripts.
Long-term gene expression. We next investigated the long-
term expression of EGFP in sorted cells transduced with either
the EIAV or HIV vector system. NB8 and HepG2 cells were
assayed for EGFP expression by flow cytometry 2 and 12 weeks
after the cell sorting. In NB8 and HepG2 cells transduced with
the E-LTR vector, there were 5-fold and 47-fold decreases,
respectively, in the numbers of EGFP-expressing cells after 12
weeks in culture (Fig. 3A). In cells transduced with the E-CMV
vector, there were nearly twofold losses of EGFP-expressing
cells in both cell lines after 12 weeks. In contrast, in NB8 and
HepG2 cells transduced with the HIV vector, there were only
slight decreases in the number of EGFP-positive cells after 12
weeks in culture. However, the horse fibroblast cell line NBL-6
transduced with E-LTR demonstrated no loss of EGFP-ex-
pressing cells over the same culture period (Fig. 3B). This
finding suggests some species specificity in the sensitivity of the
EIAV vectors to transgene-silencing mechanisms.
To ensure that the decreases in the numbers of EGFP-
expressing cells were not due to the loss of integrated EIAV
provirus in transduced cells, PCR was performed on genomic
DNAs isolated from the 12-week cultures (Fig 3C). In NB8-
and HepG2-transduced cells, there were no differences in gene
transfer levels among E-LTR-, E-CMV-, and HIV-sorted cell
lines, demonstrating that the loss of EGFP expression in
EIAV-transduced human cells was not due to loss of the pro-
virus but to gene-silencing mechanisms.
Our data demonstrate that EIAV-based vectors are effective
gene transfer vehicles in dividing and nondividing human cells,
a finding in direct contrast to those for two other nonprimate
lentivirus vectors based on caprine arthritis encephalitis virus
and visna virus (3, 12). However, other nonprimate lentiviral
vectors, such as those based on feline immunodeficiency virus,
can also effectively transduce human cells. To increase gene
transfer to G0-arrested cells, transfer vectors containing the
EIAV central polypurine tract are being developed. In contrast
to the similarities in the levels of gene transfer obtained with
EIAV- and HIV-based vectors, gene expression from EIAV-
based vectors was significantly less than that from HIV-based
vectors, due to the relative instability of EIAV-derived mRNA
transcripts. It is important to note that during the preparation
of this paper, Yamada et al. reported lower levels of EIAV-
derived mRNA than those derived from HIV vectors in a
transduced human B-cell line (16). However, the mechanism
for this difference in mRNA levels was not investigated.
To increase the duration and levels of gene expression from
EIAV vectors, modifications of EIAV vectors are necessary.
Preliminary experiments using either the woodchuck hepatitis
posttranscriptional element or the constitutive transport ele-
ment from the Mason-Pfizer monkey virus, both of which in-
crease gene expression from HIV vectors, also showed in-
creased gene expression from EIAV vectors in vitro and in vivo
(data not shown). Alterations in the EIAV core poly(A) site,
which reside in the 3 LTR, may increase gene expression by
increasing the mRNA stability of EIAV-derived vectors. Re-
moving polyadenylation sequences from HIV vectors and re-
placing them with a bovine growth hormone polyadenylation
signal increased the viral titer twofold, suggesting a possible
increase in viral RNA stability (8). Further developments in
EIAV vector design similar to improvements made in HIV and
MLV vectors, such as the creation of self-inactivating vectors
to minimize promoter interference and the elimination of pos-
sible methylation-sensitive and transcriptional repressor se-
quences found in the E-LTR, are under way.
Finally, improvements in EIAV vector design should ad-
dress the problem of the transgene silencing which was ob-
served in long-term cultures of all human cell lines (Fig. 3).
The nature of the gene-silencing mechanisms occurring in the
EIAV vectors is unclear; however, it is hypothesized that gene
silencing with retroviral vectors occurs through a two-step
mechanism, where methylation of transcriptional elements oc-
curs first, followed by repressive alterations in chromatin struc-
ture (4). However, culture of the EIAV-transduced silenced
cell lines in the presence of the DNA methyltransferase inhib-
itor 5-azacytidine or the histone deacetylase inhibitor tricho-
statin A failed to reactivate transgene expression (data not
FIG. 2. Analysis of half-lives of viral RNA from NB8 cells transduced with E-LTR, E-CMV, HIV, and MLV vectors. NB8 cells were transduced
at an MOI of 0.5 with the indicated vector, expanded, and sorted for EGFP expression. Positive cells were cultured in medium containing 10 g
of actinomycin D/ml, and total RNA was isolated at the indicated time points. For Northern blot analysis, total RNA blots were probed with
32P-labeled EGFP probes from E-LTR-, E-CMV-, HIV-, or MLV-transduced cells. The EIAV blot was overexposed to more clearly visualize the
decreasing RNA levels. An ethidium bromide-stained gel showing the 18S rRNA was used to assess RNA loading.
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shown). McInerney et al. reported that these drugs were inef-
fective in reversing retroviral vector gene silencing when ad-
ministered 3 months after vector administration, which is sim-
ilar to our findings with the EIAV vectors, suggesting that
there is a limited time period in which it is possible to reacti-
vate silenced transgenes after vector administration before si-
lencing becomes refractive to methylase or deacetylase inhib-
itors (9). Alternatively, the presence of high levels of EIAV
mRNA in human cells may impede cell growth or induce cell
death. Therefore, over the culture period, a cell population
expressing little or no EIAV mRNA would outgrow a cell
population expressing a large amount of mRNA, resulting in
an apparent loss of EGFP-expressing cells over time.
In summary, as gene transfer agents, EIAV vectors are as
effective as HIV-derived vectors. Limitations in the duration
and levels of gene expression from EIAV vectors necessitate
ongoing improvements in EIAV vector design. These modifi-
cations are needed to make EIAV-derived vectors a viable
alternative to HIV-derived vectors.
The work in this report was supported by grants AI47693 (B.A.B.)
and HL10430 (J.P.O.) from the National Institutes of Health.
REFERENCES
1. Arya, S. K., M. Zamani, and P. Kundra. 1998. Human immunodeficiency
virus type 2 lentivirus vectors for gene transfer: expression and potential for
helper virus-free packaging. Hum. Gene Ther. 9:1371–1380.
2. Berkowitz, R., H. Ilves, W. Y. Lin, K. Eckert, A. Coward, S. Tamaki, G. Veres,
and I. Plavec. 2001. Construction and molecular analysis of gene transfer
FIG. 3. Long-term gene expression. Cells were transduced at an MOI of 0.5, expanded, and sorted for EGFP expression 14 days after
transduction. The sorted cells were cultured, and the numbers of EGFP-positive cells were analyzed by flow cytometry 2 and 12 weeks later. The
number of EGFP-positive cells is indicated in the corner of each histogram. (A) HepG2 and NB8 cells. Mock, mock transduced. (B) E-LTR-
transduced NBL-6 horse fibroblast cells. (C) DNA-PCR analysis of EGFP levels in transduced cells. DNAs were isolated from HepG2- and
NB8-transduced cells cultured for 12 weeks after transduction. Primers specific for EGFP (forward, 5-CGAGCTGGACGGCGACGTAAAC-3;
reverse, 5-GCGCTTCTCGTTGGGGTCTTTG-3) or -actin (forward, 5-CATTGTGATGGACTCCGGAGACGG-3; reverse, 5-CATCTCC
TGCTCGAAGTCTAGAGC-3) were used to amplify 300 ng of DNA (30 cycles) from mock-transduced (lanes MK) or E-LTR-, E-CMV-, or
HIV-transduced cells.
1514 NOTES J. VIROL.
systems derived from bovine immunodeficiency virus. J. Virol. 75:3371–3382.
3. Berkowitz, R. D., H. Ilves, I. Plavec, and G. Veres. 2001. Gene transfer
systems derived from Visna virus: analysis of virus production and infectivity.
Virology 279:116–129.
4. Bestor, T. H. 1998. Gene silencing. Methylation meets acetylation. Nature
393:311–312.
5. Curran, M. A., S. M. Kaiser, P. L. Achacoso, and G. P. Nolan. 2000. Efficient
transduction of nondividing cells by optimized feline immunodeficiency virus
vectors. Mol. Ther. 1:31–38.
6. D’Costa, J., H. Brown, P. Kundra, A. Davis-Warren, and S. Arya. 2001.
Human immunodeficiency virus type 2 lentiviral vectors: packaging signal
and splice donor in expression and encapsidation. J. Gen. Virol. 82:425–434.
7. Follenzi, A., L. E. Ailles, S. Bakovic, M. Geuna, and L. Naldini. 2000. Gene
transfer by lentiviral vectors is limited by nuclear translocation and rescued
by HIV-1 pol sequences. Nat. Genet. 25:217–222.
8. Iwakuma, T., Y. Cui, and L. J. Chang. 1999. Self-inactivating lentiviral
vectors with U3 and U5 modifications. Virology 261:120–132.
9. McInerney, J. M., J. R. Nawrocki, and C. H. Lowrey. 2000. Long-term
silencing of retroviral vectors is resistant to reversal by trichostatin A and
5-azacytidine. Gene Ther. 7:653–663.
10. Metharom, P., S. Takyar, H. H. Xia, K. A. Ellem, J. Macmillan, R. W.
Shepherd, G. E. Wilcox, and M. Q. Wei. 2000. Novel bovine lentiviral vectors
based on Jembrana disease virus. J. Gene Med. 2:176–185.
11. Mitrophanous, K., S. Yoon, J. Rohll, D. Patil, F. Wilkes, V. Kim, S. Kings-
man, A. Kingsman, and N. Mazarakis. 1999. Stable gene transfer to the
nervous system using a non-primate lentiviral vector. Gene Ther. 6:1808–
1818.
12. Mselli-Lakhal, L., C. Favier, M. F. Da Silva Teixeira, K. Chettab, C. Legras,
C. Ronfort, G. Verdier, J. F. Mornex, and Y. Chebloune. 1998. Defective
RNA packaging is responsible for low transduction efficiency of CAEV-
based vectors. Arch Virol. 143:681–695.
13. Naldini, L., U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M.
Verma, and D. Trono. 1996. In vivo gene delivery and stable transduction of
nondividing cells by a lentiviral vector. Science 272:263–267.
14. Olsen, J. C. 1998. Gene transfer vectors derived from equine infectious
anemia virus. Gene Ther. 5:1481–1487.
15. Tarantal, A. F., J. P. O’Rourke, S. S. Case, G. C. Newbound, J. Li, C. I. Lee,
C. R. Baskin, D. B. Kohn, and B. A. Bunnell. 2001. Rhesus monkey model for
fetal gene transfer: studies with retroviral-based vector systems. Mol. Ther.
3:128–138.
16. Yamada, K., J. C. Olsen, M. Patel, K. W. Rao, and C. E. Walsh. 2001.
Functional correction of fanconi anemia group C hematopoietic cells by the
use of a novel lentiviral vector. Mol. Ther. 3:485–490.
17. Zufferey, R., J. E. Donello, D. Trono, and T. J. Hope. 1999. Woodchuck
hepatitis virus posttranscriptional regulatory element enhances expression of
transgenes delivered by retroviral vectors. J. Virol. 73:2886–2892.
VOL. 76, 2002 NOTES 1515
